Ultragenyx Pharmaceutical Inc (RARE)
46.00
-0.40
(-0.86%)
USD |
NASDAQ |
Nov 21, 16:00
46.00
0.00 (0.00%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Enterprise Value: 3.670B for Nov. 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2024 | 3.670B |
| November 19, 2024 | 3.553B |
| November 18, 2024 | 3.428B |
| November 15, 2024 | 3.518B |
| November 14, 2024 | 3.785B |
| November 13, 2024 | 3.883B |
| November 12, 2024 | 3.803B |
| November 11, 2024 | 4.070B |
| November 08, 2024 | 4.036B |
| November 07, 2024 | 4.042B |
| November 06, 2024 | 4.051B |
| November 05, 2024 | 4.204B |
| November 04, 2024 | 4.100B |
| November 01, 2024 | 4.094B |
| October 31, 2024 | 4.094B |
| October 30, 2024 | 4.170B |
| October 29, 2024 | 4.259B |
| October 28, 2024 | 4.284B |
| October 25, 2024 | 4.353B |
| October 24, 2024 | 4.446B |
| October 23, 2024 | 4.434B |
| October 22, 2024 | 4.443B |
| October 21, 2024 | 4.412B |
| October 18, 2024 | 4.578B |
| October 17, 2024 | 4.626B |
| Date | Value |
|---|---|
| October 16, 2024 | 4.711B |
| October 15, 2024 | 4.658B |
| October 14, 2024 | 4.572B |
| October 11, 2024 | 4.471B |
| October 10, 2024 | 4.358B |
| October 09, 2024 | 4.313B |
| October 08, 2024 | 4.305B |
| October 07, 2024 | 4.225B |
| October 04, 2024 | 4.350B |
| October 03, 2024 | 4.338B |
| October 02, 2024 | 4.513B |
| October 01, 2024 | 4.602B |
| September 30, 2024 | 4.513B |
| September 27, 2024 | 4.253B |
| September 26, 2024 | 4.326B |
| September 25, 2024 | 4.467B |
| September 24, 2024 | 4.534B |
| September 23, 2024 | 4.541B |
| September 20, 2024 | 4.651B |
| September 19, 2024 | 4.654B |
| September 18, 2024 | 4.554B |
| September 17, 2024 | 4.627B |
| September 16, 2024 | 4.707B |
| September 13, 2024 | 4.650B |
| September 12, 2024 | 4.566B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.201B
Minimum
Mar 16 2020
10.97B
Maximum
Dec 23 2020
3.847B
Average
3.397B
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals Inc | 30.33B |
| NovaBay Pharmaceuticals Inc | 2.745M |
| Palatin Technologies Inc | 15.49M |
| iBio Inc | 9.932M |
| Theriva Biologics Inc | -12.74M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -133.52M |
| Revenue (Quarterly) | 139.49M |
| Total Expenses (Quarterly) | 271.48M |
| EPS Diluted (Quarterly) | -1.40 |
| Gross Profit Margin (Quarterly) | 84.93% |
| Profit Margin (Quarterly) | -95.71% |
| Earnings Yield | -14.07% |
| Normalized Earnings Yield | -14.12 |